



Post Authorisation Assessments

Ridaflea Spot-on Solution for Medium Dog 134 mg

Vm 39787/4001

•	June 2020	To add validation of microbial limit for the active substance. Addition of new packaging specification for the active substance.
•	24 January 2020	Change in the ASMF holder and manufacturing process of the active substance.
•	09 October 2019	Change in the invented name of the veterinary medicinal product from Ridaflea Spot-on Solution Dog M 134 mg to Ridaflea Spot-on Solution for Medium Dog 134 mg
•	06 March 2019	Changes to the labelling and package leaflet.
•	21 November 2018	Addition of a site where batch control/testing takes place. Addition of a secondary packaging site for the finished product. Addition of a primary packaging site for the finished product. Changes in the qualitative and quantitative composition of the immediate packaging of the finished product. Change to a test procedure for the finished product. Minor change in the manufacturing process of the finished product. Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product. Addition of a manufacturing site of the finished product.
•	19 July 2018	Changes to the labelling.
•	27 July 2017	Deletion of manufacturing site for an active substance
•	01 November 2016	Change in specification parameters of the finished product.
•	28 September 2016	Renewal
•	31 March 2016	Approval of previously unseen mock ups. Change in distributor from Pfizer to Chanelle.
•	6 January 2016	To change legal distribution category from NFA-VPS to AVM-GSL.
•	11 September 2015	Change in product name
•	08 February 2012	Change in test procedure for the finished product.